Preliminary program
(per 2026-05-08)
September 17, 2026 – P53 Focus Day
08.00 – 08:45 | Registration
08:45 – 09:00 | Welcome and Opening [Bjørn Tore Gjertsen, chair, NAMLG]
Session 1 – TP53 biology and epidemiology
[Chairs: Bjørn Tore Gjertsen, Marianne Severinsen]
09:00 – 09:40 | Jean-Christophe Bourdon, SKGJ CMYC Keynote Lecture
09:40 – 10.00 | Christer Nilsson, Swedish AML Group: TP53 Epidemiology in AML
10:00 – 10:45 Coffee break
Session 2 – Diagnostic and therapeutic strategies: from bench to bed
[Chairs: Anne Louise Tølbøll Sørensen, Pia Ettala]
10:45 – 11:20 | Klas Wiman, KG Jebsen Centre Keynote Lecture
11:20 – 11:35 | Amos Tuval
11:35 – 12.05 | Shah Mithun, TP53 mutated precursor and leukemic state
12:05 – 13:20: Lunch break
Session 3 – Contemporary and novel therapy of TP53 mutated myeloid malignancies
[Chairs: Sören Lehmann, Albin Österroos]
13:20 – 13:50 | Marina Konopleva, SKGJ CMYC Keynote Lecture, TP53 mutated myeloid malignancies: Montefiore approach
13:50 – 14:10 | Anders Eivind Leren Myhre, TP53 Mutated Myeloid Neoplasms: Allo-HSCT at Any Cost?
14:10 – 14:45 | Kim Theilgaard- Mønch, NAMLG Keynote Lecture, Overcoming chemotherapy resistance in TP53 defective AML through synthetic lethal combination therapy
14:45 – 15:30 | Coffee break
Session 4 – Experimental diagnostics and -omics
[Chairs: Håkon Reikvam, Andrea Lenartova]
15:30 – 16:00 | Tor Henrik Tvedt, Title TBD
16:00 – 16:30 | Hussain Abbas, Dissecting TP53 Mutated AML Through Multi-omic Integration
16:30 – 17:30 | Industry sponsored Session #1, Otsuka
[Chair: TBD]
Title TBA; Focus on updated treatment landscape for elderly and fragile AML patients
17:45 – 19:10 | Led by Jörg Cammenga – Poster-walk with microphone; 2 min per poster; Academic and Industry presenting their posters, Snacks + drinks
19:30 – 22:30 | Conference Dinner @ Håkonshallen
September 18, 2026 – FLT3 Focus Day
08.00-09.00 | Industry Sponsored Session #2, Daiichi Sankyo
[Chair: TBD]
08:00 – 08:30 | Pau Montesinos, Clinical development of FLT3/TKI inhibitors in wild type AML: fails and successes
08:30 – 09:00 | Mark J Levis, Management of FLT3-ITD AML
Session 6 – FLT3 biology and epidemiology
[Chairs: Jörg Cammenga, Anne Sophie von Krogh]
09:00 – 09.30 | Lars Rönnstrand, FLT3 and AML: History, Biology, and Signaling Pathways
09.30 – 10.00 | Gunnar Juliusson, FLT3-ITD in AML – data from the Swedish AML Registry
10:00 – 10:45 | Coffee break
Session 7 – Approaches for FLT3 targeted therapy
[Chairs: Anne Stridsholt Roug, Daniel Tuyet Kristensen]
10:45 | Announcement of Poster Prizes
10:45 – 11:15 | Jing Tang, Computational approaches for rationalizing drug combinations in AML
11:15 – 11:45 | Ton Falques, Clonal evolution under therapy in KMT2A-rearranged leukemia in a FLT3N676K mouse model
11.45-12.05 | Yngvar Fløysand, What is the role of FLT3 TKI maintenance in FLT3+ AML?
12.05-12.25 | Marc Raajimakers, Title TBD
12:25 – 13:30 | Lunch break
Session 8 – FLT3 and the devil in the details
[Chair: Bjørn Tore Gjertsen, Sören Lehmann]
13:30 – 13.50 | Francesca Sacco, How the FLT3-ITD insertion site shapes therapy resistance: a systems biology approach
13:50 – 14.30 | Pau Montesinos, Why and how should FLT3 inhibitors work in FLT3wt AML?
14:30 – 14.50 | Mark J Levis, Using MRD to manage FLT3-mutated AML
14:50 – 15:00 | Bjørn Tore Gjertsen, Closing remarks
